Table 2. Base clinicopathological characteristics.
| Characteristics | Value | |
|---|---|---|
| Age (yr) | 49.49 ± 11.41 | |
| Subtype | ||
| HR+HER2− | 219 (52.4) | |
| HR+HER2+ | 38 (9.1) | |
| HER2 | 35 (8.4) | |
| TNBC | 126 (30.1) | |
| Histologic grade | ||
| I | 76 (18.2) | |
| II | 191 (45.7) | |
| III | 151 (36.1) | |
| pT stage | ||
| 1 | 197 (47.1) | |
| 2 | 205 (49.0) | |
| 3 | 13 (3.1) | |
| pN stage | ||
| 0 | 251 (60.0) | |
| 1 | 108 (25.8) | |
| 2 | 36 (8.6) | |
| 3 | 21 (5.0) | |
| Recurrence | 47 (11.2) | |
| Death | 47 (11.2) | |
| Median follow-up period (mo) | 65 (2–140.5) | |
Values are presented as mean ± standard deviation, number (%) or number (range).
HR+ = hormone receptor positive; HER2− = human epidermal growth factor receptor 2 negative; HER2+ = human epidermal growth factor receptor 2 positive; TNBC = triple-negative breast cancer.